A mammogram showing an abnormal finding can result in stress and anxiety for as long as 3 years for some women, even if the finding is determined to be a “false positive,” according to a study that appeared in the March/April issue of The Annals of Family Medicine.
A mammogram showing an abnormal finding can result in stress and anxiety for as long as 3 years for some women, even if the finding is determined to be a “false positive,” according to a study that appeared in the March/April issue of The Annals of Family Medicine.
The researchers in Denmark who conducted the study came to the surprising conclusion that 3 years after a false-positive finding, women experience psychosocial consequences ranging between those of women with a normal mammogram and those with a diagnosis of breast cancer.
In a cohort study with a 3-year follow-up, the researchers recruited 454 women with abnormal findings in screening mammography over a 1-year period. For each woman with an abnormal finding on a screening mammogram (false and true positives), the researchers recruited another 2 women with normal screening results who were screened the same day at the same clinic. These participants were asked to complete the Consequences of Screening in Breast Cancer questionnaire-a validated questionnaire encompassing 12 psychosocial outcomes-at baseline and at 1, 6, 18, and 36 months.
Six months after final diagnosis, women with false-positive findings reported changes in “existential values and inner calmness” as great as those reported by women with a diagnosis of breast cancer. Three years after being declared free of cancer, women with false-positive results consistently reported greater negative psychosocial consequences compared with women who had normal findings in all 12 psychosocial outcomes.
The researchers concluded that “false-positive screening mammography causes long-term psychosocial harm.”
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More